Gene therapies are already changing lives, in some cases dramatically. Children with spinal muscular atrophy who would have died in infancy are sitting up, standing, and surviving past their fifth birthdays. People with sickle cell disease are going a year or more without the agonizing pain crises that previously landed them in the hospital. Adults with an inherited form of blindness are navigating obstacle courses in dim light for the first time. These are not theoretical promises from a conference podium; they are outcomes from approved products and late-stage clinical trials. But the picture is more complicated than a simple triumph narrative. Safety risks, staggering costs, uncertain long-term durability, and deeply unequal global access all temper the optimism.
What Gene Therapy Actually Does
At its simplest, gene therapy corrects a disease by fixing the genetic instructions that caused it. Most rare diseases stem from a single faulty gene, which makes them unusually well suited for this approach. The two main strategies in use today differ in where the fix happens. In one, a working copy of the missing or broken gene is delivered directly into the patient’s body, usually packed inside a tiny virus called an adeno-associated virus (AAV). AAV has become the workhorse of the field because it can be engineered to carry therapeutic DNA into target cells and has so far proven to be one of the safer viral delivery strategies.1PubMed Central. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy In the other strategy, a patient’s own cells are removed, edited in the lab, and then returned. This is how the CRISPR-based sickle cell therapy works.
Sickle Cell Disease and the CRISPR Milestone
The FDA’s 2023 approval of Casgevy, the first therapy based on CRISPR gene editing, was a watershed moment. Sickle cell disease affects roughly 100,000 people in the United States alone, and it is caused by a single mutation that distorts red blood cells into rigid, crescent shapes. Those misshapen cells clog small blood vessels and trigger episodes of severe pain called vaso-occlusive crises, along with organ damage that shortens life expectancy.
Casgevy works by a clever indirect route. Rather than trying to fix the sickle mutation itself, it targets a gene called BCL11A that normally suppresses fetal hemoglobin production after birth. By disabling that suppressor in a patient’s blood-forming stem cells, the therapy coaxes those cells into producing high levels of fetal hemoglobin, a form that does not sickle.2PubMed Central. FDA approval of Casgevy and Lyfgenia: a dual breakthrough in gene therapies for sickle cell disease The edited stem cells are infused back into the patient after chemotherapy clears out the old marrow.
The clinical results have been striking. In an ongoing trial of 44 patients, about 94% of those who could be evaluated went at least 12 consecutive months free of severe pain crises.3PubMed Central. CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review For people who previously spent weeks every year hospitalized, that kind of freedom represents a genuine transformation in daily life. Patients who required regular blood transfusions before treatment no longer needed them.4PubMed Central. Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR/Cas9 gene therapy for sickle cell disease
Children With Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is one of the most vivid examples of gene therapy rewriting a prognosis. The most severe form, type 1, typically kills children before their second birthday. The gene therapy Zolgensma (onasemnogene abeparvovec) delivers a working copy of the missing SMN1 gene via an AAV vector in a single intravenous infusion.
Five-year follow-up data from the original trial tell a remarkable story. All ten patients who received the therapeutic dose were still alive, and none needed permanent ventilation. Children who had acquired motor milestones like head control kept them, and two patients reached the new milestone of standing with assistance.5JAMA Neurology. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy Without treatment, none of those children would have been expected to sit independently, let alone stand.
Real-world data, gathered outside the tightly controlled setting of a clinical trial, reinforce that the treatment helps most children but also reveal important nuances. In a study of 60 patients, children treated before eight months of age showed the largest gains in motor function. Children treated between eight and 24 months also improved, though less dramatically. Children older than 24 months at treatment showed no statistically meaningful motor improvement.6The Lancet Child & Adolescent Health. Real-world experience of onasemnogene abeparvovec in patients with spinal muscular atrophy The lesson is blunt: timing matters enormously. The younger the child at treatment, the better the outcome.
Why Newborn Screening Matters So Much
That age-dependent response has made newborn screening for SMA a public health priority. Many states and countries now test for SMA at birth, and the economics back up the practice. Modeling studies estimate that treating a single presymptomatic infant with gene therapy gains nearly ten additional quality-adjusted life years over 60 years compared with waiting until symptoms appear to start treatment.7Journal of Neurology, Neurosurgery & Psychiatry. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis Catching the disease before irreversible motor neuron loss takes hold is the difference between a child who walks and one who may never sit up.
Restoring Vision in Inherited Blindness
Luxturna (voretigene neparvovec) was the first gene therapy approved in the U.S. for a genetic disease, arriving in 2017 for people with a form of inherited retinal dystrophy caused by mutations in the RPE65 gene. These patients experience progressive vision loss that can lead to near-total blindness. The treatment delivers a functional copy of RPE65 directly beneath the retina in each eye.
Clinical trials showed that roughly 70% of patients maintained functional vision improvements up to four years after treatment.8PubMed Central. Clinical and pharmacovigilance safety evaluation of LUXTURNA (voretigene neparvovec-rzyl) A systematic review pooling post-approval data confirmed statistically significant improvements in light sensitivity and visual acuity across treated patients.9Survey of Ophthalmology. Post-approval outcomes of voretigene neparvovec (Luxturna®) retinal gene therapy: A systematic review and meta-analysis Real-world results from the LIGHT study showed rapid gains in functional vision at low light levels, with improvements sustained out to two years. Critically, children and adults benefited similarly.10Eye. Voretigene neparvovec in RPE65-related inherited retinal dystrophy: the 1-year real-world study LIGHT
What “improved vision” means in practice can be hard to appreciate from clinical scores. For many of these patients, the change is the ability to navigate a room without bumping into furniture, to see a child’s face in candlelight, or to walk outside at dusk without a cane. Those gains sound modest next to perfect sight, but for someone who was losing the ability to see at all, they are life-altering.
How Long Do the Effects Last
Durability is the field’s most consequential open question. Gene therapies are marketed as one-time treatments, and their price tags reflect that framing. But “one-time” only delivers value if the effect persists for decades, and the honest answer is that nobody yet knows whether it will.
Animal studies and emerging human data suggest that expression from AAV-delivered genes can last more than ten years.11PubMed Central. Durability of transgene expression after rAAV gene therapy In hemophilia B, long-term follow-up from pivotal trials has documented sustained factor IX expression for over a decade. A landmark trial showed that a single infusion raised clotting factor levels to between 1% and 6% of normal in all ten patients over a median follow-up of more than three years, cutting bleeding episodes by over 90%.12PubMed Central. Long-term safety and efficacy of factor IX gene therapy in hemophilia B Hemophilia A, however, tells a more cautious tale: factor VIII levels produced by gene therapy tend to decline over time, highlighting that durability varies by disease and by the specific gene being delivered.13PubMed. Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms
The stakes around durability extend beyond biology. Because immune responses to AAV vectors generate neutralizing antibodies that block the same virus from working a second time, re-dosing a patient if efficacy fades is currently not feasible for most AAV-based therapies.14Trends in Biotechnology. Evading and overcoming AAV neutralization in gene therapy Patients who already have antibodies from natural AAV exposure are excluded from many trials altogether. This one-shot constraint raises the urgency around making the first dose count.
Safety Is Not a Solved Problem
Gene therapy’s safety profile has improved enormously since the field’s early, troubled years. But serious adverse events still occur, and being honest about them matters. High-dose systemic AAV therapy, the kind used for diseases like SMA and Duchenne muscular dystrophy, has caused fatalities from liver, kidney, heart, or lung failure, driven primarily by immune responses to the viral vector.15PubMed Central. Lethal immunotoxicity in high-dose systemic AAV therapy
Liver toxicity deserves particular attention. Mild liver enzyme elevations are common after AAV infusion, but in rare cases the damage progresses to acute liver failure. This can require prolonged courses of immunosuppressant drugs, which carry their own risks.16Current Hepatology Reports. Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy Across multiple gene therapy clinical trials, a range of serious immune-related events has been documented, including blood-clotting disorders, respiratory distress, heart inflammation, and overwhelming inflammatory responses.17PubMed Central. Immune Toxicities in AAV Gene Therapy: Overview for Clinicians
CRISPR-based therapies carry a different category of risk: off-target editing. The system is designed to cut DNA at one precise location, but it sometimes makes unintended cuts elsewhere in the genome.18PubMed Central. Off-target effects in CRISPR/Cas9 gene editing Those stray edits can disrupt gene regulation and, in a worst-case scenario, could trigger cancerous transformations. Larger structural changes to chromosomes, including deletions and rearrangements, have also been observed at both intended and unintended cut sites.19Molecular Therapy Nucleic Acids. Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges No CRISPR therapy approved so far has produced cancer in treated patients, but the theoretical risk keeps regulators and scientists watchful, and long-term surveillance of treated individuals will continue for years.
Duchenne Muscular Dystrophy and the Limits of Current Results
Not every gene therapy program has produced unambiguous wins. Duchenne muscular dystrophy (DMD), a devastating muscle-wasting disease affecting mostly boys, has been a particularly humbling target. The dystrophin gene responsible for DMD is far too large to fit inside an AAV capsid, so researchers have engineered miniaturized versions. Delandistrogene moxeparvovec, the first FDA-approved gene therapy for DMD, delivers one such micro-dystrophin construct.
A meta-analysis of clinical trials found that treated children showed improvements on a standard motor function assessment at one year, but the effect was much stronger in four- and five-year-olds than in six- and seven-year-olds. When compared directly with untreated controls, the only measure that reached a significant difference was the time it took a child to stand up from the floor. Walking speed and stair-climbing time did not differ significantly from controls.20PubMed. Safety and efficacy of AAV-based mini- and micro-dystrophin gene therapies in Duchenne muscular dystrophy: a systematic review and meta-analysis of clinical trials These results are meaningful for families watching a child’s muscles deteriorate, but they also illustrate that gene therapy can slow or stabilize decline without fully reversing it, particularly when some damage has already occurred.
The Cost Barrier
Gene therapy prices have no precedent in medicine. Zolgensma launched at roughly $2.1 million per dose, and sickle cell therapies carry similar price tags. These numbers provoke visceral reactions, but the economic argument for one-time treatments is more nuanced than it first appears. For hemophilia, where lifelong clotting factor replacement can cost hundreds of thousands of dollars a year, modeling studies have found that gene therapies would produce lower overall costs and better health outcomes than conventional treatment, provided the therapeutic effect lasts at least ten years.21PubMed Central. A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B The word “provided” does a lot of work in that sentence; long-term value depends on assumptions about durability that remain unproven.
For sickle cell disease gene therapy, the projected ten-year budget impact on the U.S. Medicaid system alone ranges from roughly $8 billion to $15 billion, depending on pricing assumptions.22PubMed. Financial Impacts of Paying for Gene Therapy for Sickle Cell Disease Under Alternative Pricing and Financing Mechanisms That kind of figure threatens to break conventional insurance models, where premiums are calculated around predictable annual spending. A single patient needing treatment in a given year can destabilize a small health plan’s budget. Researchers and policymakers have proposed alternatives including installment payments, outcomes-based rebates where manufacturers refund money if the therapy fails, and reinsurance pools that spread costs across many payers.23PubMed. Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies None of these models has been widely adopted yet.
Manufacturing Is Harder Than It Looks
Even if cost and access barriers were resolved on paper, actually producing enough gene therapy to meet demand is its own challenge. AAV vectors are biological products made in living cells, and the manufacturing process is plagued by variability, low yields, and difficulty scaling up.24PubMed Central. Advancing AAV vector manufacturing: challenges, innovations, and future directions for gene therapy A batch might produce a large number of empty viral shells that contain no therapeutic DNA alongside the functional ones, and separating the two is technically demanding. Improvements in purification methods are helping, but gene therapy manufacturing remains far more artisanal than the mass production of, say, a small-molecule pill.
For ex vivo therapies like Casgevy, the complexity is different but equally daunting. Each patient’s cells must be individually collected, shipped to a specialized facility, edited, quality-tested, and shipped back, all while the patient undergoes chemotherapy to prepare their bone marrow. The process takes months and requires infrastructure that few hospitals outside major academic centers possess.
Who Gets Left Out
The global distribution of gene therapy access is starkly unequal. As of 2021, the only lower- and middle-income countries with approved gene therapy products were China, Brazil, and the Philippines. A search of clinical trial registries found that while high-income countries hosted numerous recruiting trials with multiple sites, no open gene therapy trials existed in low-income or lower-middle-income countries.25PubMed Central. Gene therapy access: Global challenges, opportunities, and views from Brazil, South Africa, and India This matters acutely for diseases like sickle cell, where the highest burden falls on sub-Saharan Africa and South Asia, precisely the regions least likely to have access to a multimillion-dollar therapy requiring advanced hospital infrastructure.26PubMed. The translational gap for gene therapies in low- and middle-income countries
What Families Actually Experience
Clinical trial numbers do not capture what gene therapy feels like from the patient’s side. A scoping review of the lived experience of families going through pediatric gene therapy found that published literature is overwhelmingly focused on how patients and caregivers think about the therapy beforehand, weighing risks against benefits, agonizing over timing, and seeking clear communication from medical teams, rather than on what the experience itself is like.27PubMed. The Lived Experience of Pediatric Gene Therapy: A Scoping Review The accounts that do exist reveal enormous emotional weight. Parents describe feeling caught between hope and terror, knowing the therapy might transform their child’s future but also that serious adverse reactions are possible.
Caregiver perspectives also surface a less-discussed tension around identity. In a study of families affected by Rett syndrome, some caregivers, especially relatives of older individuals, expressed concern that gene therapy might change who their family member fundamentally is. They described worry about whether the person with Rett syndrome would want to “change who they are” and whether altering the condition might actually reduce a quality of life the individual currently experiences as happy.28Rare. Family and caregiver perspectives on gene therapy for Rett syndrome These are not fringe concerns. For conditions diagnosed in childhood that shape decades of lived experience, the question of what counts as a benefit becomes more personal and philosophical than any clinical score can capture.
Ethical Dimensions in Pediatric Trials
Most rare diseases targeted by gene therapy affect children, which adds layers of ethical complexity. Children cannot consent for themselves, trials often lack standard placebos because withholding treatment for a fatal disease is ethically fraught, and the irreversibility of gene therapy means a decision made by parents on behalf of a toddler cannot be undone. Researchers have flagged the need to proactively address the uncertainty and risk involved, the fact that participating in one gene therapy trial may preclude a child from future trials, and the burden of long-term monitoring that can stretch for 15 years or more after treatment.29PubMed. Somatic Gene Therapy Research in Pediatric Populations: Ethical Issues and Guidance for Operationalizing Early Phase Trials
Regulatory Shortcuts and Their Trade-Offs
Because rare diseases affect small populations and often progress slowly, running traditional large-scale clinical trials to prove a therapy works can take longer than some patients have. The FDA’s accelerated approval pathway allows drugs onto the market based on surrogate endpoints, measurements that are “reasonably likely” to predict a real clinical benefit rather than proving one outright. For gene therapy, this might mean approving a treatment based on how much therapeutic protein it produces rather than waiting years to see whether patients live longer or function better.
The pathway has enabled faster access, but it creates tension. There is persistent uncertainty about which surrogate endpoints regulators will accept, and an expectation to demonstrate a quantitative link between the surrogate and clinical benefit that some researchers argue is unrealistic for rare diseases. The concern is that some therapies that are genuinely safe and effective may be delayed or never reach patients because the evidence bar, while well-intentioned, does not flex enough for tiny patient populations.30Molecular Therapy. Gene Therapies Transform Rare Diseases. Are They Changing Lives?
Non-Viral Alternatives on the Horizon
Many of the field’s current limitations trace back to its reliance on AAV vectors: the antibody problem that prevents re-dosing, the immune reactions that cause toxicity, the manufacturing bottleneck. Lipid nanoparticles, the same basic technology that delivered mRNA COVID-19 vaccines, are being explored as an alternative delivery system. They offer a potential way around the antibody barrier because, unlike viral vectors, they have not been observed to generate the neutralizing immune response that blocks repeat doses.31Molecular Therapy. Lipid Nanoparticle Systems for Enabling Gene Therapies Lipid nanoparticles also integrate safety and efficacy features into a single delivery platform, making them attractive for future gene editing applications.32PubMed Central. Lipid nanoparticles for gene delivery
These systems are not yet ready to replace AAV for most gene therapy applications. Efficiently delivering large DNA payloads to specific tissues remains harder with lipid nanoparticles than with viruses that have evolved over millions of years to enter cells. But the research is advancing quickly, and the prospect of a re-dosable, less immunogenic delivery vehicle could eventually reshape how gene therapies are designed and priced. If a therapy could be given more than once, the pressure to make every single dose permanent would ease, and so would the justification for multimillion-dollar pricing.